Even with national strategies in place to end the HIV epidemic, almost 1.2 million people remain at risk of sexually acquired HIV.1 But, there are ways you and your team can help patients lower their risk. Giving patients the knowledge they need, building trust through thorough conversations, and encouraging adherence to PrEP medication are just a few topics that are discussed in this broadcast.
1. Smith DK, et al. Ann Epidemiol. 2018;28(12):850-857.
Please click HERE to see full Prescribing Information for DESCOVY® (emtricitabine 200mg/tenofovir alafenamide 25 mg tablets) for HIV-1 pre-exposure prophylaxis (PrEP), including BOXED WARNING.